• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

趋化因子和可溶性CD40配体在自身免疫性血小板减少性紫癜患者中的意义。

Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura.

作者信息

Nagahama Minori, Nomura Shosaku, Kanazawa Shigenori, Ozaki Yoshio, Kagawa Hideo, Fukuhara Shirou

机构信息

First Department of Internal Medicine, Kansai Medical University, Osaka Japan.

出版信息

Eur J Haematol. 2002 Nov-Dec;69(5-6):303-8. doi: 10.1034/j.1600-0609.2002.02774.x.

DOI:10.1034/j.1600-0609.2002.02774.x
PMID:12460235
Abstract

We investigated the levels of various chemokines and soluble CD40L (sCD40L) in ITP patients, in order to determine the influence of CD40-CD40L interaction on the pathogenesis of ITP. We found increases in MCP-1 and RANTES levels in ITP patients compared with those in healthy individuals. Thirty-eight of the 65 ITP patients (58.5%) had elevated levels of sCD40L. We found significant decreases in platelet counts in sCD40L-positive ITP patients. Although the sCD40L level did not differ significantly between the control and nonimmune thrombocytopenia groups, but among ITP patients. sCD40L level was significantly higher in those with untreated ITP than in those with treated ITP. In addition, significant increases in RANTES, MCP-1, sCD14, and sP-selectin levels were observed in sCD40L-positive ITP patients, although sE-selectin levels were not increased in such patients. For other factors examined, however, there were no differences in level between sCD40L-positive and -negative ITP patients. These findings suggests that there are two groups of ITP patients, one with elevated and one with normal of sCD40L. ITP cases in which sCD40L was increased appeared to involve changes in platelet counts and monocyte activation. The pathogenesis of ITP may in some patients include alterations of the CD40/CD40L pathway.

摘要

我们研究了免疫性血小板减少症(ITP)患者体内各种趋化因子和可溶性CD40配体(sCD40L)的水平,以确定CD40 - CD40L相互作用对ITP发病机制的影响。我们发现,与健康个体相比,ITP患者的单核细胞趋化蛋白-1(MCP - 1)和调节激活正常T细胞表达和分泌因子(RANTES)水平升高。65例ITP患者中有38例(58.5%)的sCD40L水平升高。我们发现sCD40L阳性的ITP患者血小板计数显著降低。虽然对照组和非免疫性血小板减少症组之间的sCD40L水平无显著差异,但在ITP患者中,未治疗的ITP患者的sCD40L水平显著高于接受治疗的患者。此外,sCD40L阳性的ITP患者中,RANTES、MCP - 1、可溶性CD14(sCD14)和可溶性P选择素(sP - 选择素)水平显著升高,不过此类患者的可溶性E选择素(sE - 选择素)水平并未升高。然而,对于其他检测因素,sCD40L阳性和阴性的ITP患者之间水平并无差异。这些发现表明存在两组ITP患者,一组sCD40L水平升高,另一组正常。sCD40L升高的ITP病例似乎涉及血小板计数变化和单核细胞激活。ITP的发病机制在一些患者中可能包括CD40/CD40L途径的改变。

相似文献

1
Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura.趋化因子和可溶性CD40配体在自身免疫性血小板减少性紫癜患者中的意义。
Eur J Haematol. 2002 Nov-Dec;69(5-6):303-8. doi: 10.1034/j.1600-0609.2002.02774.x.
2
Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.心房颤动中的可溶性CD40配体、血小板表面CD40配体及血小板总CD40配体:与可溶性P-选择素、卒中危险因素及危险因素干预的关系
Chest. 2008 Sep;134(3):574-581. doi: 10.1378/chest.07-2745. Epub 2008 Jul 18.
3
Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura.在再生障碍性贫血和免疫性血小板减少性紫癜中,血浆细胞因子减少与血小板计数降低有关。
J Thromb Haemost. 2012 Aug;10(8):1616-23. doi: 10.1111/j.1538-7836.2012.04757.x.
4
Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia--possible role of platelet activation.子痫前期中可溶性CD40配体、RANTES和GRO-α浓度升高——血小板活化的可能作用
Thromb Haemost. 2001 Nov;86(5):1272-6.
5
Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP).血小板生成素受体激动剂对原发性免疫性血小板减少症(ITP)患者循环细胞因子和趋化因子水平的影响。
Platelets. 2017 Jul;28(5):478-483. doi: 10.1080/09537104.2016.1235691. Epub 2016 Nov 7.
6
Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.自身免疫性血小板减少症:流式细胞术检测外周血T和B淋巴细胞上血小板相关的CD154/CD40L和CD40
Hematology. 2007 Aug;12(4):301-7. doi: 10.1080/10245330701383957.
7
Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L.两种新型抗CD40L单克隆抗体的表征与应用:细胞膜CD40L的表位与功能研究及可溶性血清CD40L的起源研究
Tissue Antigens. 2004 Sep;64(3):257-63. doi: 10.1111/j.1399-0039.2004.00257.x.
8
Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.匹伐他汀对高脂血症患者单核细胞趋化蛋白-1的影响。
Blood Coagul Fibrinolysis. 2009 Sep;20(6):440-7. doi: 10.1097/MBC.0b013e32832e0618.
9
Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia.免疫性血小板减少症患者的 Th1(CXCL10)和 Th2(CCL2)趋化因子表达。
Hum Immunol. 2010 Jun;71(6):586-91. doi: 10.1016/j.humimm.2010.02.010. Epub 2010 Mar 7.
10
Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty.术前可溶性CD40L水平可预测冠状动脉成形术后炎症反应增强及再狭窄。
Circulation. 2003 Dec 2;108(22):2776-82. doi: 10.1161/01.CIR.0000103700.05109.0D. Epub 2003 Nov 17.

引用本文的文献

1
Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme.停药后持续缓解(SROT)的 TPO-RAs:布尔戈斯 Eltrombopag 逐步停药方案的十个步骤。
Medicina (Kaunas). 2023 Mar 27;59(4):659. doi: 10.3390/medicina59040659.
2
Platelets in ITP: Victims in Charge of Their Own Fate?特发性血小板减少性紫癜中的血小板:自己命运的主宰者?
Cells. 2021 Nov 19;10(11):3235. doi: 10.3390/cells10113235.
3
Emerging Therapies in Immune Thrombocytopenia.免疫性血小板减少症的新兴疗法
J Clin Med. 2021 Mar 2;10(5):1004. doi: 10.3390/jcm10051004.
4
Cytokine changes during treatment of anti-Caspr2 encephalitis: a case report.抗 Caspr2 脑炎治疗期间的细胞因子变化:病例报告。
BMC Neurol. 2020 Aug 13;20(1):299. doi: 10.1186/s12883-020-01879-x.
5
Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation.Wiskott-Aldrich 综合征血小板缺陷在诱导自身免疫和炎症中的自主作用。
J Allergy Clin Immunol. 2018 Oct;142(4):1272-1284. doi: 10.1016/j.jaci.2017.12.1000. Epub 2018 Feb 6.
6
Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain.罗米司亭减量和停药后原发性免疫性血小板减少症患者的持续缓解:西班牙现实生活管理中的病例系列
Case Rep Hematol. 2017;2017:4109605. doi: 10.1155/2017/4109605. Epub 2017 Jun 11.
7
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.促血小板生成素治疗慢性免疫性血小板减少症患者的调节性 T 细胞活性增强。
Blood. 2010 Nov 25;116(22):4639-45. doi: 10.1182/blood-2010-04-281717. Epub 2010 Aug 5.
8
Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE.单核细胞趋化蛋白-1 -2518 A/G单核苷酸多态性可能与系统性红斑狼疮的肾脏疾病和血小板减少症有关。
J Biomed Biotechnol. 2010;2010:130265. doi: 10.1155/2010/130265. Epub 2010 Apr 21.
9
Pathobiology of secondary immune thrombocytopenia.继发性免疫性血小板减少症的病理生物学
Semin Hematol. 2009 Jan;46(1 Suppl 2):S2-14. doi: 10.1053/j.seminhematol.2008.12.005.
10
Future innovations in anti-platelet therapies.抗血小板治疗的未来创新。
Br J Pharmacol. 2008 Jul;154(5):918-39. doi: 10.1038/bjp.2008.151. Epub 2008 Apr 21.